Liquid Biopsy & MRD Testing: Can a Blood Test Detect Cancer Before a Scan?
Understanding One of the Most Advanced Tools in Modern Oncology
After successful colon cancer surgery, scans may appear normal.
But an important question remains:
Has every cancer cell been removed?
This is where liquid biopsy and Minimal Residual Disease (MRD) testing are changing cancer care.
What Is a Liquid Biopsy?
Liquid biopsy is a blood test that analyzes tiny fragments of tumor DNA circulating in the bloodstream.
These fragments are known as circulating tumor DNA (ctDNA).
What Is MRD?
MRD stands for Minimal Residual Disease.
Even after successful treatment, microscopic traces of cancer may sometimes remain in the body.
These cells may be too small to appear on scans.
MRD testing may detect evidence of residual disease before recurrence becomes visible.
Potential Benefits
- Earlier detection of recurrence risk
- Personalized follow-up planning
- Additional treatment guidance
- More precise surveillance strategies
Why This Matters
The future of cancer care is moving from reactive treatment to proactive monitoring.
